View
42
Download
0
Category
Tags:
Preview:
DESCRIPTION
Scientific Symposium. Opening session CTOS (1 pm to 5 pm) CTOS reception (5pm to 6pm) Dinner/Consensus Discussion (6pm to 9 pm) Panel George Demetri, MD Scott Schuetze, MD, PhD Laurence Baker, DO (moderator). P=Participating NP=Not Participating *Awaiting Contract **No longer accruing. - PowerPoint PPT Presentation
Citation preview
Scientific Symposium
• Opening session CTOS (1 pm to 5 pm)
• CTOS reception (5pm to 6pm)
• Dinner/Consensus Discussion (6pm to 9 pm)– Panel
• George Demetri, MD• Scott Schuetze, MD, PhD• Laurence Baker, DO (moderator)
P=Participating NP=Not Participating *Awaiting Contract **No longer accruing
start date
GleevecNov ’01
G Vs. Gem/TXT STSJan ’03
Columbia 15 NP
Emory NP P*
Mayo NP 6
MD Anderson 45 20
U of Michigan 69 29
Memorial Sloan Kettering 34 11
National Cancer Institute NP P
Partners
Dana Farber
Massachusetts General
NP 1
UofCalifornia Los Angeles NP P*
Washington Cancer Center 14 10
Lutheran General ** 42 10
Total 219 87
CR
PR
SDSD
CR
PR
PD PD
Month 2 Month 4
PRACTICAL ADVANTAGES OF THE BAYESIAN DESIGN
PRACTICAL ADVANTAGES OF THE BAYESIAN DESIGN
The hierarchical model allows data from each subtype to provide information about parameters in all other subtypes
It avoids two undesirable approaches, conducting :
- One trial, assuming one common parameter, ignoring the subtypes, or
- Separate trials that ignore each others’ data
User-friendly front ends greatly facilitate trial conduct
0.0 0.2 0.4 0.6 0.8 1.0
-12
-10
-8-6
-4-2
0.0 0.2 0.4 0.6 0.8 1.0
Angiosarcoma
Ewings
Fibrosarcoma
Leiomyosarcoma
Liposarcoma
MFH
Osteosarcoma
PNS
Rhabdomyosarcoma
Synovial
Desmoid
= Pr( Response )
95% Posterior Credible Intervals by Histologic Subtype
Pre-Gleevec
8 weeks on Rx
H &. E
cKIT
74 yo man with myofibroblastic sarcoma
Pre-Gleevec
2 weeks on Rx
H & E
cKIT
65 yo man with malignant fibrous histiocytoma
Planned Studies
• Gemcitabine/docetaxel in bone sarcomas
• Imatinib neoaduvant treatment of DFSP
• AMG 706 Phase II trial in sarcoma
• BMS SRC inhibitor
• Ziopharm active ifosphamide moiety
• Uterine sarcoma adjuvant therapy
Recommended